Navigation Links
Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
Date:4/1/2009

WALTHAM, Mass., April 1 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI), announced today that the company will present research findings from a large clinical study on the genetics of osteoporosis and vertebral fractures at the 8th International Symposium on Osteoporosis: Translating Research into Clinical Practice, on April 4, 2009 at the Marriott Wardman Park Hotel in Washington, D.C. The Company's research poster, titled "Identification of Inflammatory Gene Variants as Biomarkers of Osteoporosis Risk in Asian Women," highlights genetic predisposition risk factors in Asian women for vertebral fractures and osteoporosis and will be presented at 9:45 a.m. in Exhibit Hall C.

The cross-sectional study evaluated over 1,200 Korean and Japanese female subjects. Predisposition for vertebral fracture and elevated bone biomarkers were investigated in candidate genes linked to osteoporosis, with statistical adjustments made for known risk factors such as age, body mass index and drug treatment. The research found Korean women in the study were seventy percent more likely to get vertebral fracture if they carried a genetic variation, also called single nucleotide polymorphism (SNP), in the IL-10 gene, while those who carried a SNP in the IL1-RN gene were fifty percent more predisposed to vertebral fracture. The study results also revealed differences in genetic markers between Asian and Caucasian post-menopausal women, despite high susceptibility for disease among both populations.

The study, which was conducted in collaboration with Yonsei University in Seoul, Korea, enrolled a sample of 838 Korean women between the ages of 60 to 84 years and 400 Japanese women within 36 months post-menopause.

"While studies exist that look at the genetics of osteoporosis, there has been minimal research into the genetic risk for vertebral fractures," commented Nazneen Aziz, Vice President of Research and Development. "Spinal or vertebral fractures (VF) are a common clinical manifestation of osteoporosis and often lead to serious consequences, including loss of height, severe back pain, and deformity. These new findings should be valuable both in guiding the medical management of osteoporosis by identifying high-risk patients and in the smarter design of clinical drug trials for vertebral fracture treatment."

About Osteoporosis

According to the National Osteoporosis Foundation, osteoporosis is a disease in which bones become fragile and more likely to break. Chronic hyper-inflammation is thought to be an underlying causative factor in osteoporosis. If not prevented or if left untreated, osteoporosis can progress painlessly until a bone breaks. More than 100 million Asian women are estimated to have osteoporosis. The prevalence of osteoporosis is similar between Caucasians and Asian women. The prevalence of osteoporosis in the Japanese female population aged 50 to 79 years is estimated to be about 35 percent. In China, the prevalence of vertebral fracture is about 30 percent for women aged 70 to 79 years, while in India the number of osteoporosis patients was approximately 26 million in 2003, with the numbers projected to increase to 36 million by 2013.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
2. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
3. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
6. Interleukin Genetics Wins International Award for Outstanding Research Published in the Journal, Nutrition
7. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
8. Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Genetics Determine Optimal Drug Dose of Common Anticoagulant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2017)... 19, 2017  Mako Medical Laboratories partnered with Secretary ... Family Assistance Fund (MFA) to bring 140 soldiers back ... with their families one last time before being deployed. ... travel and logistics needed for these soldiers. "Mako Medical ... their families. We just wish we could bring them ...
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/12/2017)... , July 12, 2017 CarpalAID is a revolutionary ... braces or surgery. Carpal tunnel syndrome affects more than ... at twice the rate of men. The common methods of treating ... mobilization with uncomfortable hand braces or gloves. ... CarpalAID is a clear patch ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 21, 2017 , ... How physicians and athletic trainers assess ... researchers presenting their work at the American Orthopaedic Society for Sports Medicine’s ... the patterns of change in concussion symptom presentation, diagnostic tools used and length ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital stays or who ... in such facilities are specially designed to accommodate patients with a wide range of ... inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, a specially designed ...
(Date:7/20/2017)... ... July 20, 2017 , ... Doctors on Liens, the leading network of ... Chiropractic , directed by Dr. Russell Horine, DC to their exclusive list of medical ... Dr. Russell Horine serving as the clinic director and his son Dr. Lee Horine ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... **An FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... passing inspections and boosting quality. , It’s known as the “CY2016 Annual FDA ...
Breaking Medicine News(10 mins):